途深智合：科学超智能驱动的新药创造 Scientific Superintelligence-Driven Drug Creation

途深智合（Toursynbio）是一家专注于 AI 创新药研发的科技企业，于 2023 年成立，拥有由人工智能、计算生物学、结构生物学、药物研发等领域专家组成的海内外交叉学科研发团队。公司致力于打造面向未来的自主智能生物医药研发工厂（Autonomous AI Biopharma Foundry），推动生物医药研发从“科学智能”迈向“科学超智能”，从“药物发现”迈向“药物创造”，从“工具辅助”迈向“自主创新”。公司自主研发的 ToursynClaw 大分子药物设计科学超智能体平台，融合自研蛋白大模型、科学智能体和全自动机器人实验产线，构建“AI 设计—自动化验证—数据迭代”的完整研发飞轮，实现从靶点分析、蛋白质设计、分子优化到实验验证和反馈学习的端到端智能化创新药研发流程。 ToursynClaw 平台是途深智合自 2023 年以来持续迭代发展的第四代 AI 大分子药物设计平台，历经 ProteinEngine 蛋白质大模型（2023）、TourSynbio 蛋白质设计大模型（2024）、ProteinNova 大分子药物设计智能体（2025）等阶段，逐步形成融合多模态基础模型、领域模型与科学智能体的新一代生物医药研发体系。基于 AI Agent 与 Wet Lab Agent 深度协同的干湿闭环体系，途深智合可实现约 1.5 个月完成抗体设计及功能实验验证，大幅缩短传统研发周期。目前，公司已实现半年内推动 16 条抗体药管线完成 PCC 阶段验证，相关动物实验结果均获得积极反馈；同时，在 GPCR、无序区等传统难成药靶点设计领域取得全球领先的实测效果，成为国内少数实现 AI 蛋白设计计算能力与实体实验工业化体系真正打通的科创企业。基于 ToursynClaw 构建的生物药管线超级工厂将重塑 AI 驱动生物制药的新范式，加速 AI 原生生物医药创新体系落地，推动自主智能生物医药研发工厂建设。 Toursynbio is an AI-driven drug discovery and development technology company founded in 2023. The company brings together a global interdisciplinary R&D team of experts in artificial intelligence, computational biology, structural biology, and drug development. Toursynbio is committed to building a future-oriented Autonomous AI Biopharma Foundry, advancing biopharmaceutical R&D from Scientific Intelligence to Scientific Superintelligence, from drug discovery to drug creation, and from tool-assisted research to autonomous innovation. Its independently developed ToursynClaw macromolecular drug design Scientific Superintelligence platform integrates proprietary protein foundation models, scientific agents, and fully automated robotic experimental production lines, forming a complete R&D flywheel of AI design, automated validation, and data iteration. This enables an end-to-end intelligent drug innovation workflow covering target analysis, protein design, molecular optimization, experimental validation, and feedback learning. ToursynClaw is the fourth-generation AI macromolecular drug design platform continuously developed by Toursynbio since 2023. It has evolved through ProteinEngine protein foundation model (2023), TourSynbio protein design foundation model (2024), and ProteinNova macromolecular drug design agent (2025), gradually forming a next-generation biopharmaceutical R&D system that integrates multimodal foundation models, domain-specific models, and scientific agents. Based on a dry-wet closed-loop system powered by deep collaboration between AI Agent and Wet Lab Agent, Toursynbio can complete antibody design and functional experimental validation in approximately 1.5 months, significantly shortening the traditional R&D cycle. The company has advanced 16 antibody drug pipelines to PCC-stage validation within six months, with positive results from related animal studies. It has also achieved globally leading experimental performance in traditionally difficult-to-drug target areas such as GPCRs and intrinsically disordered regions, making it one of the few technology companies in China to truly connect AI protein design computation with an industrialized physical experimental system. The biologics pipeline super factory built on ToursynClaw will reshape the paradigm of AI-driven biopharmaceutical development, accelerate the implementation of AI Native biopharmaceutical innovation, and promote the construction of Autonomous AI Biopharma Foundry.